Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
ARA-290
Also known as: Cibinetide, Erythropoietin-derived peptide
ARA-290 (cibinetide) is a synthetic 11-amino acid peptide derived from the B helix of erythropoietin (EPO). Unlike EPO, it does not bind the classical EPO receptor or stimulate erythropoiesis. Instead, it selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and beta-common receptor. It has been tested in Phase II clinical trials for sarcoidosis-related neuropathy, diabetic neuropathy, and other conditions.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 1208243-50-8 |
| Molecular Formula | C52H85N15O18 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Selectively activates the innate repair receptor (IRR/EPOR-betacR heterodimer) without binding classical EPO receptors. This provides tissue-protective and anti-inflammatory effects without erythropoietic stimulation. Promotes Schwann cell and neural progenitor survival, reduces inflammation, and supports tissue repair in metabolically stressed environments.
Dosing Research
Clinical trials used 2-8 mg subcutaneously daily or three times weekly. Phase II studies in diabetic neuropathy used 4 mg SC daily for 28 days. Self-reported underground use generally follows clinical trial dosing. Treatment courses of 4-12 weeks have been studied.
Side Effects & Risks
Well-tolerated in Phase II clinical trials with adverse event rates similar to placebo. Injection site reactions were the most common complaint. No hematological effects (no increase in red blood cells). Headache and nausea reported occasionally. Long-term safety beyond 12 weeks is less characterized.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.